

WEST Search History

DATE: Thursday, September 28, 2006

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L4	L3 and l2	11
<input type="checkbox"/>	L3	olanzapine same pamoate	50
<input type="checkbox"/>	L2	(424/489).ccls. or (514/220).ccls.	5320
		<i>DB=PGPB; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L1	20040097489.pn.	1

END OF SEARCH HISTORY

WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Thursday, September 28, 2006

Hide? Set Name Query**Hit Count***DB=PGPB; PLUR=YES; OP=ADJ*

<input type="checkbox"/>	L3	20040097489.pn.	1
<input type="checkbox"/>	L2	(olanzapine and pamoate).clm.	6
<input type="checkbox"/>	L1	(olanzapine pamoate and oleaginous).clm.	2

END OF SEARCH HISTORY

Interference Search history 9/28/06 BR

WEST Search History

DATE: Thursday, September 28, 2006

Hide?	Set Name	Query	Hit Count
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L17	5736152.pn.	2
<input type="checkbox"/>	L16	5888533.pn.	2
<input type="checkbox"/>	L15	L14 and L13	38
<input type="checkbox"/>	L14	olanzapine	1614
<input type="checkbox"/>	L13	pamoic acid	1730
<input type="checkbox"/>	L12	olanzapine pamoate monohydrate	5
<input type="checkbox"/>	L11	L9 with L8	9
<input type="checkbox"/>	L10	L9 and L8	310
<input type="checkbox"/>	L9	\$59benzodiazepine	10591
<input type="checkbox"/>	L8	pamoate	6488
<input type="checkbox"/>	L7	4977150.pn.	2
<input type="checkbox"/>	L6	4997150.pn.	2
<input type="checkbox"/>	L5	4997150	16
<input type="checkbox"/>	L4	5602897.pn.	2
<input type="checkbox"/>	L3	5229382.pn. or wo-9629995\$.did. or wo-9630375\$.did. or wo-9811893\$.did.	5
<input type="checkbox"/>	L2	olanzapine pamoate	13
	<i>DB=PGPB; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L1	20040097489.pn.	1

END OF SEARCH HISTORY

10613619

L8 ANSWER 1 OF 4 USPATFULL on STN

APPLICANT

ACCESSION NUMBER: 2004:127505 USPATFULL
TITLE: 2-methyl-thieno-benzodiazepine formulation
INVENTOR(S): Allen, Douglas J., Indianapolis, IN, UNITED STATES
Dekemper, Kurt D., Franklin, IN, UNITED STATES
Ferguson, Thomas H., Greenfield, IN, UNITED STATES
Garvin, Stuart J., Plainfield, IN, UNITED STATES
Murray, Linda C., Noblesville, IN, UNITED STATES
Brooks, Norman D., Greenfield, IN, UNITED STATES
Bunnell, Charles A., Lafayette, IN, UNITED STATES
Mascarenhas, Snehlata S., Indianapolis, IN, UNITED STATES
Shinkle, Sharon L., Indianapolis, IN, UNITED STATES
Hendriksen, Barry A., Guildford, UNITED KINGDOM
Tupper, David E., Reading, UNITED KINGDOM
Sanchez-Felix, Manuel V., Grayshot, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004097489	A1	20040520
APPLICATION INFO.:	US 2003-613619	A1	20030703 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-136887, filed on 1 May 2002, GRANTED, Pat. No. US 6617321 Continuation of Ser. No. US 2000-509757, filed on 29 Mar 2000, ABANDONED A 371 of International Ser. No. WO 1998-US20426, filed on 30 Sep 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-60493P	19970930 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN, 46206-6288	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1719	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM [0032] Aqueous suspensions of olanzapine, olanzapine pamoate salts or solvates thereof include the PLURONICS, such as PLURONIC F68, which at the appropriate concentrations gels at body temperature. PLURONIC concentrations in the range of 40-45% in the presence of olanzapine gels at body temperature and would be a preferred.

SUMM [0033] Alternatively, aqueous suspensions of cellulosic or polysaccharide gums, including sodium carboxymethyl cellulose or sodium alginate, may provide prolonged release of olanzapine, olanzapine pamoate or solvates thereof. Other natural.

SUMM [0034] Non-aqueous compositions include but are not limited to the hydrophobic PLURONICS, propylene glycols, polyethylene glycols and oleaginous formulations. Hydrophobic PLURONICS include those with a hydrophile/lipophile balance of less than 8 and may be

Blessing Fubara

incorporated individually with olanzapine, olanzapine pamoate salts. .

- SUMM . . . have any observable chemical reactions, and has no observable physiological reactions when administered into the body. The preferred oils are vegetable oils such as soybean oil, peanut oil, sesame oil, cottonseed oil, corn oil, olive oil, castor oil, palm oil, almond oil, refined fractionated oils, such as MIGLYOL 810, MIGLYOL 812, and the like and derivatized oils, such as, MIGLYOL 840, and the like. A. . .
- SUMM . . . compositions of SDHB with release modifying agents in concentrations of up to about 20% by weight, such as propylene glycol, PLURONICS, celluloses, lecithins, oils and the like may be used to modify or prolong release of olanzapine.
- SUMM [0102] PLURONIC=nonionic surfactants which are block copolymers of propylene oxide and ethylene oxide. The propylene oxide block is sandwiched between two ethylene. . .
- SUMM [0104] NF=National Formulary=meets standards for polaxamers which is the generic designation for pluronics
- SUMM [0106] PLURONICS F68
- SUMM [0107] PLURONICS F 68NF
- SUMM [0108] PLURONICS L121
- SUMM [0109] PLURONICS L092
- DETD [0124] PLURONICS®: PLURONIC® F68NF (50 g) was mixed in 111 ml of HLCP grade water. The mixture was intermittently stirred with a spatula. . . mixture was cooled and stirred until a clear solution resulted. Olanzapine (300 mg) was mixed with 10 ml of the PLURONIC® solution with a spatula until homogenous. The mixture was kept refrigerated until used.
- DETD . . . using substantially the same procedure described in Example 1.

Ex. No.	Active	Vehicle	Conc. of Active in vehicle	
2	O--F	45% PLURONIC F68NF, aq	30	mg/ml
3	O--F	45% PLURONIC F68, aq	30	mg/g
4	O--F	45% PLURONIC F68NF, aq	90	mg/ml
5	O--F	41% PLURONIC F68NF, aq	30	mg/ml
6	O--F	41% PLURONIC F68NF, aq	90	mg/ml
7	O--C	40% PLURONIC F68, aq	40	mg/ml
8	O--F	45% PLURONIC F68, aq	31	mg/ml
9	O--F	41% PLURONIC F68, aq.	30	mg/ml
10	O--F	41% PLURONIC F68, aq.	90	mg/ml
11	O--F	45% PLURONIC F68, aq.	120	mg/ml
12	O--F	41% PLURONIC F68, aq.	120	mg/ml
DETD	51	O--C Ethyl oleate	30 mg/ml	
52	O--C	Benzyl alcohol	30 mg/ml	
53	O--C	Benzyl benzoate	30 mg/ml	
54	O	PLURONIC L121	30 mg/g	
55	O--F	PLURONIC L092	30 mg/ml	
56	O--F	PLURONIC L121	30 mg/ml	

CLM What is claimed is:

4. A formulation of claim 1 wherein said carrier is selected from the group consisting of PLURONICS, cellulosic, gums, polysaccharide gums, vegetable oils, refined fractionated oils, sucrose diacetate hexaisobutyrate, chitosan, lecithin, and POVIDONE.

10613619

5. A formulation as claimed in claim 4 wherein said carrier is selected from the group consisting of PLURONICS, cellulosic gums, polysaccharide gums, vegetable oils, and refined fractionated oils.

17. A formulation as claimed in claim 16 wherein the oleaginous carrier is selected from the group consisting of PLURONICS, cellulosic gums, polysaccharide gums, vegetable oils, and refined fractionated oils

IT 132539-06-1P, Olanzapine 221373-09-7P 221373-12-2P 221373-14-4P
221373-18-8P 221373-22-4P 221373-25-7P 221373-29-1P
(preparation and formulation of)

L8 ANSWER 2 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2003:38169 USPATFULL

TITLE: 2-methyl-thieno-benzodiazepine formulation

INVENTOR(S): Allen, Douglas J., Indianapolis, IN, UNITED STATES
Dekemper, Kurt D., Franklin, IN, UNITED STATES
Ferguson, Thomas H., Greenfield, IN, UNITED STATES
Garvin, Stuart J., Plainsfield, IN, UNITED STATES
Murray, Linda C., Noblesville, IN, UNITED STATES
Brooks, Norman D., Greenfield, IN, UNITED STATES
Bunnell, Charles A., Lafayette, IN, UNITED STATES
Mascarenhas, Snehlata S., Indianapolis, IN, UNITED STATES
Shinkle, Sharon L., Indianapolis, IN, UNITED STATES
Hendriksen, Barry A., Guildford, UNITED KINGDOM
Tupper, David E., Reading, UNITED KINGDOM
Sanchez-Felix, Manuel V., Grayshott, UNITED KINGDOM

Applicant

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003027816	A1	20030206
	US 6617321	B2	20030909
APPLICATION INFO.:	US 2002-136887	A1	20020501 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-509757, filed on 29 Mar 2000, ABANDONED A 371 of International Ser. No. WO 1998-US20426, filed on 30 Sep 1998, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-60493P	19970930 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN, 46206-6288	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1727	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM [0032] Aqueous suspensions of olanzapine, olanzapine pamoate salts or

Blessing Fubara

solvates thereof include the PLURONICS, such as PLURONIC F68, which at the appropriate concentrations gels at body temperature. PLURONIC concentrations in the range of 40-45% in the presence of olanzapine gels at body temperature and would be a preferred.

SUMM [0033] Alternatively, aqueous suspensions of cellulosic or polysaccharide gums, including sodium carboxymethyl cellulose or sodium alginate, may provide prolonged release of olanzapine, olanzapine pamoate or solvates thereof. Other natural.

SUMM [0034] Non-aqueous compositions include but are not limited to the hydrophobic PLURONICS, propylene glycols, polyethylene glycols and oleaginous formulations. Hydrophobic PLURONICS include those with a hydrophile/lipophile balance of less than 8 and may be incorporated individually with olanzapine, olanzapine pamoate salts.

SUMM . . . have any observable chemical reactions, and has no observable physiological reactions when administered into the body. The preferred oils are vegetable oils such as soybean oil, peanut oil, sesame oil, cottonseed oil, corn oil, olive oil, castor oil, palm oil, almond oil, refined fractionated oils, such as MIGLYOL 810, MIGLYOL 812, and the like and derivatized oils, such as, MIGLYOL 840, and the like. A.

SUMM . . . compositions of SDHB with release modifying agents in concentrations of up to about 20% by weight, such as propylene glycol, PLURONICS, celluloses, lecithins, oils and the like may be used to modify or prolong release of olanzapine.

SUMM . . . sodium carboxymethyl cellulose, sodium salt with respect to

Wrt BRIJ®-52 polyoxoethylene (2) cetyl ether surfactant

Carnauba wax

G-1726® polyoxyethylene (20) sorbitol beeswax derivative

PLURONIC nonionic surfactants which are block copolymers of propylene oxide and ethylene oxide. The propylene oxide block is sandwiched between two.

SUMM . . . content in the molecule.

NF National Formulary = meets standards for polaxamers which is the generic designation for pluronics

LF and D low foam version Includes:

PLURONICS F68
PLURONICS F 68NF
PLURONICS L121
PLURONICS L092

MIGLYOL 810 triglycerides of the fractionated vegetable fatty acids C8 and C10 (caprylic/capric acids)

MIGLOYOL 812 differs from 810.

DETD [0096] PLURONICS®: PLURONIC® F68NF (50 g) was mixed in 111 ml of HLCP grade water. The mixture was intermittently stirred with a spatula. . . mixture was cooled and stirred until a

10613619

clear solution resulted. Olanzapine (300 mg) was mixed with 10 ml of the PLURONIC® solution with a spatula until homogenous. The mixture was kept refrigerated until used.

DETD . . . using substantially the same procedure described in Example 1.

Ex. No.	Active	Vehicle	Conc. of Active in vehicle
2	O--F	45% PLURONIC F68NF, aq	30 mg/ml
3	O--F	45% PLURONIC F68, aq	30 mg/g
4	O--F	45% PLURONIC F68NF, aq	90 mg/ml
5	O--F	41% PLURONIC F68NF, aq	30 mg/ml
6	O--F	41% PLURONIC F68NF, aq	90 mg/ml
7	O--C	40% PLURONIC F68, aq	40 mg/ml
8	O--F	45% PLURONIC F68, aq	31 mg/ml
9	O--F	41% PLURONIC F68, aq.	30 mg/ml
10	O--F	41% PLURONIC F68, aq.	90 mg/ml
11	O--F	45% PLURONIC F68, aq.	120 mg/ml
12	O--F	41% PLURONIC F68, aq.	120 mg/ml
DETD	. . .	CREMAPHOR EL	30 mg/ml
51	O--C	Ethyl oleate	30 mg/ml
52	O--C	Benzyl alcohol	30 mg/ml
53	O--C	Benzyl benzoate	30 mg/ml
54	O	PLURONIC L121	30 mg/g
55	O--F	PLURONIC L092	30 mg/ml
56	O--F	PLURONIC L121	30 mg/ml

CLM What is claimed is:

4. A formulation of claim 1 wherein said carrier is selected from the group consisting of PLURONICS, cellulosic, gums, polysaccharide gums, vegetable oils, refined fractionated oils, sucrose diacetate hexaisobutyrate, chitosan, lecithin, and POVIDONE.

5. A formulation as claimed in claim 4 wherein said carrier is selected from the group consisting of PLURONICS, cellulosic gums, polysaccharide gums, vegetable oils, and refined fractionated oils.

17. A formulation as claimed in claim 16 wherein the oleaginous carrier is selected from the group consisting of PLURONICS, cellulosic gums, polysaccharide gums, vegetable oils, and refined fractionated oils

IT 132539-06-1P, Olanzapine 221373-09-7P 221373-12-2P 221373-14-4P
221373-18-8P 221373-22-4P 221373-25-7P 221373-29-1P
(preparation and formulation of)

L8 ANSWER 3 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2001:1771 USPATFULL

TITLE: 2-methyl-thieno-benzodiazepine formulation

INVENTOR(S): Bunnell, Charles Arthur, Lafayette, IN, United States
Ferguson, Thomas Harry, Greenfield, IN, United States
Hendriksen, Barry Arnold, Guildford, United Kingdom
Sanchez-Felix, Manuel Vicente, Grayshott, United Kingdom
Tupper, David Edward, Reading, United Kingdom

Applicant

Blessing Fubara

10613619

PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6169084	B1	20010102
APPLICATION INFO.:	US 1998-163769		19980930 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-60493P	19970930 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Raymond, Richard L.	
ASSISTANT EXAMINER:	Coleman, Brenda	
LEGAL REPRESENTATIVE:	Palmberg, Arleen	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1546	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof..

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM Aqueous suspensions of olanzapine, olanzapine pamoate salts or solvates thereof include the PLURONICS, such as PLURONIC F68, which at the appropriate concentrations gels at body temperature. PLURONIC concentrations in the range of 40-45% in the presence of olanzapine gels at body temperature and would be a preferred.

SUMM Alternatively, aqueous suspensions of cellulosic or polysaccharide gums, including sodium carboxymethyl cellulose or sodium alginate, may provide prolonged release of olanzapine, olanzapine pamoate or solvates thereof. Other natural.

SUMM Non-aqueous compositions include but are not limited to the hydrophobic PLURONICS, propylene glycols, polyethylene glycols and oleaginous formulations. Hydrophobic PLURONICS include those with a hydrophile/lipophile balance of less than 8 and may be incorporated individually with olanzapine, olanzapine pamoate salts.

SUMM . . . have any observable chemical reactions, and has no observable physiological reactions when administered into the body. The preferred oils are vegetable oils such as soybean oil, peanut oil, sesame oil, cottonseed oil, corn oil, olive oil, castor oil, palm oil, almond oil, refined fractionated oils, such as MIGLYOL 810, MIGLYOL 812, and the like and derivatized oils, such as, MIGLYOL 840, and the like. A.

SUMM . . . compositions of SDHB with release modifying agents in concentrations of up to about 20% by weight, such as propylene glycol, PLURONICS, celluloses, lecithins, oils and the like may be used to modify or prolong release of olanzapine.

DETD . . . carboxymethyl cellulose, sodium salt

Wrt = with respect to
BRIJ®-52 = polyoxoethylene(2)cetyl ether
surfactant

Carnauba = wax
G-1726® = polyosyethylene (20)serbitol

Blessing Fubara

10613619

PLURONIC = beeswax derivative
nonionic surfactants which are
block copolymers of propylene
oxide and ethylene oxide. The
propylene oxide block is
sandwiched between. . .

DETD NF = National Formulary = meets
standards for polaxamers which is
the generic designation for
pluronics

LF and D = low foam version
Includes:
PLURONICS F68
PLURONICS F 68NF
PLURONICS L121
PLURONICS L092

MIGLYOL 810 = triglycerides of the fractionated
vegetable fatty acids C8 and C10
(caprylic/capric acids)

MIGLOYOL 812 = differs from 810. . .

DETD PLURONICS®: PLURONIC® F68NF (50 g) was mixed
in 111 ml of HLCP grade water. The mixture was intermittently stirred
with a spatula. . . mixture was cooled and stirred until a clear
solution resulted. Olanzapine (300 mg) was mixed with 10 ml of the
PLURONIC® solution with a spatula until homogenous. The
mixture was kept refrigerated until used.

DETD	Ex. No.	Active	Vehicle	Conc. of Active in vehicle
	2	O-F	45% PLURONIC F68NF, aq	30 mg/ml
	3	O-F	45% PLURONIC F68, aq	30 mg/g
	4	O-F	45% PLURONIC F68NF, aq	90 mg/ml
	5	O-F	41% PLURONIC F68NF, aq	30 mg/ml
	6	O-F	41% PLURONIC F68NF, aq	90 mg/ml
	7	O-C	40% PLURONIC F68, aq	40 mg/ml
	8	O-F	45% PLURONIC F68, aq	31 mg/ml
	9	O-F	41% PLURONIC F68, aq.	30 mg/ml
	10	O-F	41% PLURONIC F68, aq.	90 mg/ml
	11	O-F	45% PLURONIC F68, aq.	120 mg/ml
	12	O-F	41% PLURONIC F68, aq.	120 mg/ml

DETD . . . CREMAPHOR EL 30

	mg/ml		
51	O-C	Ethyl oleate	30 mg/ml
52	O-C	Benzyl alcohol	30 mg/ml
53	O-C	Benzyl benzoate	30 mg/ml
54	O	PLURONIC L121	30 mg/g
55	O-F	PLURONIC L092	30 mg/ml
56	O-F	PLURONIC L121	30 mg/ml

IT 132539-06-1P, Olanzapine 221373-09-7P 221373-12-2P 221373-14-4P
221373-18-8P 221373-22-4P 221373-25-7P 221373-29-1P
(preparation and formulation of)

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 1999:233762 CAPLUS

DOCUMENT NUMBER: 130:257362

TITLE: Methylthienobenzodiazepine derivative antipsychotic
drug formulation.

INVENTOR(S): Allen, Douglas James; Dekemper, Kurt Douglas;
Ferguson, Thomas Harry; Garvin, Stuart James; Murray,
Linda Cameron; Brooks, Norman Dale; Bunnell, Charles

Applicant

Blessing Fubara

10613619

Arthur; Hendriksen, Barry Arnold; Mascarenhas,
Snehlata Singh; Shinkle, Sharon Louise; Sanchez-Felix,
Manuel Vicente; Tupper, David Edward
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9916313	A1	19990408	WO 1998-US20426	19980930
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2304568	AA	19990408	CA 1998-2304568	19980930
AU 9895914	A1	19990423	AU 1998-95914	19980930
AU 752552	B2	20020919		
EP 1018880	A1	20000719	EP 1998-949632	19980930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9813228	A	20000829	BR 1998-13228	19980930
TR 200000812	T2	20010723	TR 2000-200000812	19980930
JP 2001517685	T2	20011009	JP 2000-513467	19980930
NZ 503641	A	20020927	NZ 1998-503641	19980930
MX 200003040	A	20001110	MX 2000-3040	20000328
NO 2000001631	A	20000530	NO 2000-1631	20000329
HR 2000000181	A1	20001231	HR 2000-181	20000331
HR 20000181	B1	20060731		
US 2003027816	A1	20030206	US 2002-136887	20020501
US 6617321	B2	20030909		
US 2004097489	A1	20040520	US 2003-613619	20030703
PRIORITY APPLN. INFO.:				
			US 1997-60493P	P 19970930
			WO 1998-US20426	W 19980930
			US 2000-509757	B1 20000329
			US 2002-136887	A1 20020501
AB The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2.3-b][1.5]benzodiazepine (olanzapine) (preparation given) or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.				
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT				
IT 57-88-5, Cholest-5-en-3-ol (3 β)-, uses 59-02-9, α -Tocopherol 112-80-1, Oleic acid, uses 303-43-5, Cholesterol oleate 601-34-3, Cholesterol palmitate 1406-18-4, Vitamin E 1510-21-0, Cholesterol hemisuccinate 8051-73-8, G 1726 9003-39-8, Povidone 9004-32-4, Sodium carboxymethylcellulose 9004-95-9, Brij-52 9005-64-5, Tween 20 9005-65-6, Tween 80 9012-76-4, Chitosan 25322-68-3 35602-69-8, Cholesterol stearate 77466-09-2, Miglyol 840 106392-12-5, Pluronic F68 130249-48-8, Crothix				
RL: MOA (Modifier or additive use); USES (Uses)				

Blessing Fubara

10613619

(olanzapine antipsychotic drug formulation ingredient)
IT 132539-06-1P, Olanzapine 221373-09-7P 221373-12-2P 221373-14-4P
221373-18-8P 221373-22-4P 221373-25-7P 221373-29-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
study); PREP (Preparation); USES (Uses)
(preparation and formulation of)